ISG to Study Analytics, AI Services for Life Sciences
MWN-AI** Summary
Information Services Group (ISG) has initiated a research study focusing on specialist providers of analytics and AI services specifically for the life sciences sector. This study aims to assess how these providers can help life sciences enterprises accelerate innovation and improve patient outcomes through integrated data management across various functions, including research, clinical operations, commercial activities, and post-market evaluation.
The findings from this research will culminate in the ISG Provider Lens® report entitled "Specialty Analytics and AI Services — Life Sciences," scheduled for release in September 2026. This report will specifically evaluate companies that deliver customized analytics and AI solutions, excluding larger platform vendors and service providers.
Given the increasing reliance on data and AI technologies, life sciences organizations are turning to specialized analytics services to enhance their digital transformation efforts. Key applications of these services include predictive modeling for drug discovery, optimizing clinical trial protocols, and improving sales effectiveness. Advanced AI methodologies, such as generative and agentic AI, are also utilized to gain insights into disease progression and treatment efficiency, which are critical for informed decision-making within R&D, clinical, and commercial contexts.
The study will survey approximately 20 specialty analytics and AI service providers. ISG will develop a quadrant analysis to classify these companies based on their ability to deliver scalable analytics solutions in highly regulated environments. Analysts Manav Deep Sachdeva and Saravanan M S will author the report, which covers a global market overview for these specialized services.
ISG’s extensive research methodology incorporates customer experience data, ensuring that enterprises can make informed decisions regarding vendor selection. Overall, this study positions ISG as a pivotal resource for life science firms striving to harness the full potential of analytics and AI in enhancing operational efficiency and patient care.
MWN-AI** Analysis
As the landscape of life sciences continues to evolve, the upcoming ISG Provider Lens® report on Specialty Analytics and AI Services is poised to offer critical insights that can shape investment and operational strategies within the sector. With the data and AI revolution at the forefront, enterprises in life sciences are increasingly seeking specialized vendors to drive innovation and enhance patient outcomes. Here are key considerations for stakeholders:
1. **Focus on Specialized Providers**: The ISG report emphasizes the importance of working with specialist analytics and AI service providers. Unlike broader platform vendors, these players offer tailored solutions that address specific challenges in R&D, clinical trials, and pharmacovigilance. Enterprises should prioritize partnerships with providers that demonstrate expertise in operationalizing analytics at scale within regulated environments.
2. **Leverage Next-Gen Analytics**: The integration of advanced techniques such as predictive modeling, GenAI, and agentic AI is crucial for optimizing drug discovery and trial execution. Enterprises must assess providers based on their ability to deploy these next-generation analytics effectively. Strategic investments in companies with strong capabilities in these areas may lead to significant competitive advantages.
3. **Regulatory Readiness and Compliance**: As data volumes from clinical and real-world sources grow, the challenge of adhering to strict privacy regulations intensifies. It's essential to partner with providers that not only excel in analytics but also prioritize secure, actionable insights while ensuring compliance. This will enhance the operational productivity and regulatory readiness of the enterprise.
4. **Actionable Insights from the ISG Report**: Once released, the ISG report will serve as a valuable tool for evaluating vendor relationships and making informed selections. The comprehensive market analysis and empirical data will empower enterprises to navigate the complexities of sourcing in the analytics and AI space effectively.
In conclusion, as life sciences enterprises prepare for the future, aligning with the right partners while leveraging insights from the ISG report can significantly enhance their capacity for innovation and improve patient outcomes.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Upcoming ISG Provider Lens ® report will evaluate specialist providers helping life sciences enterprises accelerate innovation, improve patient outcomes
Information Services Group ( ISG ) (Nasdaq: III ), a global AI-centered technology research and advisory firm, has launched a research study examining specialist providers of analytics and AI services that integrate data across research, clinical, commercial and post-market functions of the life sciences industry.
The study results will be published in a comprehensive ISG Provider Lens ® report, called Specialty Analytics and AI Services — Life Sciences, scheduled to be released in September 2026. The report will cover companies offering specialized analytics and AI services to life sciences enterprises, excluding platform vendors and large service providers.
Enterprise buyers will be able to use information from the report to evaluate their current vendor relationships, potential new engagements and available offerings, while ISG advisors use the information to recommend providers to the firm’s buy-side clients.
As data and AI become central to life sciences innovation and operations, enterprises are increasingly relying on specialist analytics and AI services providers to accelerate digital transformation. Organizations are applying next-generation analytics, including predictive modeling, to derisk drug discovery, optimize clinical trial design and execution, accelerate time to market and enhance sales effectiveness. Through advanced AI techniques such as GenAI and agentic AI, they are generating in-depth insights into disease progression, treatment effectiveness and safety, supporting more informed decision-making across R&D, clinical and commercial functions.
“Growing volumes of clinical and real-world data present a significant opportunity for life sciences enterprises, yet innovation must advance within strict privacy and compliance frameworks,” said Namratha Dharshan, chief business leader at ISG. “Specialist providers play a critical role in enabling secure, actionable analytics adoption that improves regulatory readiness, operational productivity and patient outcomes.”
ISG has distributed surveys to approximately 20 specialty analytics and AI service providers. Working in collaboration with ISG’s global advisors, the research team will produce one quadrant representing the analytics and AI services that typical life sciences enterprises are buying, based on ISG’s experience working with its clients. The quadrant is:
- Specialty Analytics and AI Services — Life Sciences , evaluating providers delivering custom analytics and AI solutions across the life sciences value chain. Providers are assessed on their ability to operationalize analytics at scale within highly regulated environments and demonstrate expertise spanning R&D analytics, clinical trials and pharmacovigilance.
The study will cover the global market for specialty analytics and AI services in the life sciences and examine products and services available globally. ISG analysts Manav Deep Sachdeva and Saravanan M S will serve as authors of the report.
A list of identified providers and vendors and further details on the study are available in this digital brochure . Companies not listed as specialty analytics and AI service providers for the life sciences industry can contact ISG and ask to be included in the study.
All 2026 ISG Provider Lens ® evaluations feature expanded customer experience (CX) data that measures actual enterprise experience with specific provider services and solutions, based on ISG’s continuous CX research.
About ISG Provider Lens ® Research
The ISG Provider Lens ® Quadrant research series is the only service provider evaluation of its kind to combine empirical, data-driven research and market analysis with the real-world experience and observations of ISG’s global advisory team. Enterprises will find a wealth of detailed data and market analysis to help guide their selection of appropriate sourcing partners, while ISG advisors use the reports to validate their own market knowledge and make recommendations to ISG’s enterprise clients. The research currently covers providers offering their services globally, across Europe, as well as in the U.S., Canada, Mexico, Brazil, the U.K., France, Benelux, Germany, Switzerland, the Nordics, Australia and Singapore/Malaysia, with additional markets to be added in the future. For more information about ISG Provider Lens research, please visit this webpage .
About ISG
ISG (Nasdaq: III ) is a global AI-centered technology research and advisory firm. A trusted partner to more than 900 clients, including 75 of the world’s top 100 enterprises, ISG is a long-time leader in technology and business services that is now at the forefront of leveraging AI to help organizations achieve operational excellence and faster growth. The firm, founded in 2006, is known for its proprietary market data, in-depth knowledge of provider ecosystems, and the expertise of its 1,600 professionals worldwide working together to help clients maximize the value of their technology investments.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260219756105/en/
Press Contacts:
Laura Hupprich, ISG
+1 203-517-3100
laura.hupprich@isg-one.com
Julianna Sheridan, Matter Communications for ISG
+1 978-518-4520
isg@matternow.com
FAQ**
How does Information Services Group Inc. III plan to assess the effectiveness of specialty analytics and AI services in improving regulatory readiness and operational productivity in life sciences enterprises?
What specific metrics will Information Services Group Inc. III use to evaluate providers in the Specialty Analytics and AI Services — Life Sciences report?
In what ways will Information Services Group Inc. III ensure comprehensive coverage of global market trends while evaluating specialty analytics and AI service providers?
How can companies not listed as specialty analytics and AI service providers for life sciences request inclusion in the upcoming Information Services Group Inc. III report?
**MWN-AI FAQ is based on asking OpenAI questions about Information Services Group Inc. (NASDAQ: III).
NASDAQ: III
III Trading
-2.71% G/L:
$3.95 Last:
176,491 Volume:
$4.04 Open:
